AM 281
(Synonyms: 1-(2,4-二氯苯基)-5-(4-碘苯基)-4-甲基-N-吗啉-1H-吡唑-3-甲酰胺) 目录号 : GC16480
AM 281是一种高亲和力和特异性的选择性CB2受体拮抗剂，其IC50为13μM。AM 281用于研究内源性大麻素系统在各种生理和病理过程中的作用，具有在炎症、疼痛和神经退行性疾病研究中的潜在应用价值。
Cas No.:202463-68-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
AM 281 is a high-affinity and selective CB2 receptor antagonist with an IC50 of 13μM[1]. AM 281 is used to study the role of the endocannabinoid system in various physiological and pathological processes and has potential applications in the research of inflammation, pain, and neurodegenerative diseases[2]. AM 281 selectively activates the CB2 receptor, which is mainly expressed in immune cells and peripheral tissues, while having minimal activation of the CB1 receptor expressed in the central nervous system[3]. AM 281 has been shown to modulate immune responses and has potential therapeutic applications in diseases related to the endocannabinoid system[4].
In vitro, AM 281 (2μM) was used to pre-treat myocardial HL-1 cells for 30 minutes, followed by co-incubation with quetiapine (Que, 2μM) for 24 hours. AM 281 significantly reduced quetiapine-induced myocardial cell damage. AM 281 inhibited the activation of necroptosis by reducing the protein levels of RIP3 and MLKL and inhibiting the phosphorylation of MLKL in myocardial cells. Additionally, AM 281 significantly decreased inflammation and fibrosis in myocardial cells, improving their pathological state[5]. AM 281 (1, 2, and 4μmol/L) was used to pre-treat rat embryonic ventricular myocardial-derived H9c2 cells for 2 hours, followed by co-incubation with doxorubicin (DOX, 1 or 5μM) for 18 hours. AM 281 significantly increased cell viability and inhibited DOX-induced DNA damage and apoptosis[6].
In vivo, AM 281 (0.62, 1.25, and 2.5mg/kg) was administered via intraperitoneal injection to mice that had been treated with morphine (30-90mg/kg) for 3 consecutive days. AM 281 (2.5mg/kg) significantly improved the recognition index (RI) and alleviated memory deficits in mice undergoing spontaneous morphine withdrawal by inhibiting the activation of CB1 receptors[7]. AM 281 (1, 2, and 4mg/kg) was administered via intraperitoneal injection 30 minutes before the first re-exposure to the aversive context in mice. The results showed that AM 281 at a dose of 1mg/kg significantly increased freezing behavior (fear response) in mice[8].
References:
[1] Kadoi Y, Hinohara H, Kunimoto F, et al. Cannabinoid antagonist AM 281 reduces mortality rate and neurologic dysfunction after cecal ligation and puncture in rats. Crit Care Med. 2005 Nov;33(11):2629-36.
[2] Droste SM, Saland SK, Schlitter EK, et al. AM 251 differentially effects food-maintained responding depending on food palatability. Pharmacol Biochem Behav. 2010 Jun;95(4):443-8.
[3] Rutkowska M, Jamontt J, Gliniak H. Effects of cannabinoids on the anxiety-like response in mice. Pharmacol Rep. 2006 Mar-Apr;58(2):200-6.
[4] Gifford AN, Bruneus M, Gatley SJ, et al. Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther. 1999 Feb;288(2):478-83.
[5] Li X, Peng Z, Zhou Y, Wang J, et al. Quetiapine induces myocardial necroptotic cell death through bidirectional regulation of cannabinoid receptors. Toxicol Lett. 2019 Oct 1;313:77-90.
[6] Mukhopadhyay P, Bátkai S, Rajesh M, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007 Aug 7;50(6):528-36.
[7] Vaseghi G, Rabbani M, Hajhashemi V. The effect of AM281, a cannabinoid antagonist, on memory performance during spontaneous morphine withdrawal in mice. Res Pharm Sci. 2013 Jan;8(1):59-64.
[8] Lisboa SF, Gomes FV, Silva AL, et al. Increased Contextual Fear Conditioning in iNOS Knockout Mice: Additional Evidence for the Involvement of Nitric Oxide in Stress-Related Disorders and Contribution of the Endocannabinoid System. Int J Neuropsychopharmacol. 2015 Jan 24;18(8):pyv005.
AM 281是一种高亲和力和特异性的选择性CB2受体拮抗剂，其IC50为13μM[1]。AM 281用于研究内源性大麻素系统在各种生理和病理过程中的作用，具有在炎症、疼痛和神经退行性疾病研究中的潜在应用价值[2]。AM 281能够选择性地激活主要表达于免疫细胞和外周组织的CB2受体，而对中枢神经系统中表达的CB1受体激活作用较弱[3]。AM 281已被证明可以调节免疫反应，并在内源性大麻素系统相关的疾病中具有潜在的治疗应用价值[4]。
在体外，AM 281（2μM）预处理心肌HL-1细胞30分钟，随后与喹硫平（Que，2μM）共孵育24小时，AM 281显著减轻了喹硫平诱导的心肌细胞损伤。AM 281通过抑制CB1R，减少了心肌细胞中RIP3和MLKL的蛋白水平，并抑制了MLKL的磷酸化，从而阻断了细胞坏死样凋亡（necroptosis）的激活过程。此外，AM 281还显著降低了心肌细胞的炎症反应和纤维化程度，改善了心肌细胞的病理状态[5]。AM 281（1、2、4μmol/L）预处理大鼠胚胎心室肌源性H9c2细胞2小时，随后与多柔比星（DOX，1或5μM）共孵育18小时，AM 281显著提高了细胞的存活率，抑制了DOX诱导的DNA损伤和细胞凋亡[6]。
在体内，AM 281（0.62、1.25和2.5mg/kg）通过腹腔注射治疗接受吗啡（30-90mg/kg）给药的小鼠，连续3天。AM 281（2.5mg/kg）显著改善了记忆识别指数（RI），AM 281通过抑制CB1受体的激活，减轻了自发吗啡戒断引起的小鼠记忆障碍[7]。AM 281在（1、2和4mg/kg）通过腹腔注射给药后30分钟，对小鼠进行第一次对恐惧环境的再暴露。结果显示，AM 281在1mg/kg剂量下显著增加了小鼠的冻结行为（恐惧反应）[8]。
| Cell experiment [1]: | |
Cell lines | Rat embryonic ventricular myocardial H9c2 cells |
Preparation Method | AM 281 (1, 2, 4 μmol/L) pre-treats rat embryonic ventricular myogenic H9c2 cells for 2h, followed by co-incubation with doxorubicin (DOX, 1 or 5μM) for 18h. |
Reaction Conditions | 0, 1, 2, and 4μmol/L; 20h |
Applications | AM 281 significantly prevented cell death and apoptosis induced by doxorubicin (DOX) in H9c2 cells. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice and inducible nitric oxide synthase (iNOS) knockout (KO) mice |
Preparation Method | Male C57BL/6J and iNOS KO mice (8–12 weeks old) were used. For the fear conditioning experiment, mice were subjected to contextual fear conditioning (CFC) by exposing them to three inescapable electrical footshocks (0.75mA, 2 seconds each) in a conditioning chamber. Freezing behavior was evaluated 24, 48, 72, and 96 hours after conditioning. For drug treatment, AM 281 (1, 2, and 4mg/kg) was administered intraperitoneally (i.p.) 30 minutes before the first reexposure to the context chamber. |
Dosage form | 1, 2, and 4mg/kg; i.p |
Applications | AM 281 (1mg/kg) significantly increased freezing behavior in wild-type (WT) mice during contextual fear conditioning, indicating enhanced fear expression. However, in iNOS KO mice, AM 281 did not alter baseline freezing behavior but facilitated fear extinction when administered before reexposure to the context chamber. |
References: | |
| Cas No. | 202463-68-1 | SDF | |
| 别名 | 1-(2,4-二氯苯基)-5-(4-碘苯基)-4-甲基-N-吗啉-1H-吡唑-3-甲酰胺 | ||
| 化学名 | 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-morpholino-1H-pyrazole-3-carboxamide | ||
| Canonical SMILES | IC1=CC=C(C=C1)C2=C(C)C(C(NN3CCOCC3)=O)=NN2C(C(Cl)=C4)=CC=C4Cl | ||
| 分子式 | C21H19Cl2IN4O2 | 分子量 | 557.22 |
| 溶解度 | ≥ 1.86mg/mL in DMSO with ultrasonic and warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7946 mL | 8.9731 mL | 17.9462 mL |
| 5 mM | 0.3589 mL | 1.7946 mL | 3.5892 mL |
| 10 mM | 0.1795 mL | 0.8973 mL | 1.7946 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet